Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings outcomes as we speak.
Reported gross sales elevated 5.2% year-over-year to $22.5 billion.
GAAP earnings decreased 37.5% to $2.7 billion whereas EPS fell 34% to $1.11 in comparison with final 12 months. Adjusted EPS was down 9% to $2.42.
For full-year 2024, JNJ expects reported gross sales of $88.4-88.8 billion and adjusted EPS of $9.88-9.98.
(This story can be up to date shortly with an infographic)
BREAKING Ryerson Holding Corp (RYI) reported Q4 2025 earnings per share of $-1.01, missing the consensus estimate of $-0.65 by...
As stock markets continue to be volatile, investors looking for a stable income stream can bolster their portfolios with the...
Magnificent 7 tech stocks on display at the Nasdaq.Adam Jeffery | CNBCWhile the prospect of a SpaceX initial public offering...
How can we please our future robotic overlords if we cannot communicate with them? Audio capabilities for artificial intelligence allow...
It’s early February… There’s still time to get on the right track and flip your account in 2026. For example,...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
